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outcomes evaluated included change from baseline in trough forced expiratory 
volume in 1 second (FEV1) and COPD exacerbations leading to hospitalizations. 
Efficacy of tiotropium was presented as the mean difference to placebo. Results: 
Difference in change from baseline in FEV1 versus placebo was evaluated in 21 RCTs. 
The relative effect of tiotropium increased over time, ranging from 0.084 to 0.150 
in 2000 (launch) and from 0.120 to 0.189 in 2012. Difference in rates of exacerba-
tions versus placebo was reported in 24 studies. The relative effect of tiotropium 
was found to decrease over time for this outcome. This trend was partly explained 
by an increase in placebo effect. ConClusions: We identified variations in the 
relative efficacy of tiotropium over time on two major outcomes for assessing drug 
relativeness effectiveness in COPD. Further research is required to understand these 
changes and the implications for evaluating the relative effectiveness of a new drug 
versus already marketed ones. Time of marketing authorization may not be the 
appropriate time to assess the relative effectiveness of a new drug.
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objeCtives: to test the efficacy of two educational interventions to improve 
the inhalation techniques in patients with Chronic Obstructive Pulmonary 
Disease. Methods: Design: Multicenter Randomised Controlled Trial 
ISRCTN60147249. Patients: 220 COPD patients (to detect a difference between 
groups of 25%, 80% statistical power, 95% confidence level, 40% expected losses), 
with inhaled treatment, written consent. Non-probabilistic consecutive sam-
pling. Allocation: Patients were randomised using block randomization into three 
cohorts: InterA, IntervB, control. Variables: Primary outcomes: Performance of cor-
rect inhalation technique. Secondary outcomes: Pick flow, Baseline dyspnea index 
(BDI), Functional status (forced spirometry). Interventions: Intervention-A: Written 
information. A leaflet with the correct inhalation technique for the main inhaler 
devices used in our area. Intervention-B: Intervention-A + individual training (by 
instructors). Follow-up: 12 month, visits: baseline, 1 month, 3rd month, 6th month, 
12th month. Statiscal analysis: Mean, frequency, 95% confidence interval at baseline. 
Number Needed to Treat for a benefit (NNT) was calculated. Intention to treat analy-
sis. Results: Predominance of males (85.5%), mean age 70.54 years (CI95%, 69.38-
71.7); FEV1(mean)= 54.2% (IC95%, 51.81-56.55), mixed respiratory pattern (62.5%). 
Severity stage: 11.4% mild, 47.4% Moderate, 41.4% Severe. Pharmacological treat-
ment: inhaled-beta2-adrenergic (81.7%); inhaled-anticholinergic (76.3%); inhaled-
corticosteroids (75.3%); mucolitycs (13.7%); xanthine (5%); oral-corticosteroids (0.9%). 
BDI: grade 2. There were no statistically significative differences between groups at 
baseline. Primary outcome: The 88.1% of patients did not perform a correct inhala-
tion technique: 88.5% with Handihaler, 83.3% with Turbuhaler, 81.7% with Accuhaler 
and 79.1% with pMDI. There were statistically significative differences between con-
trol and intervention A (p= 0.023), NNT= 8.62 (IC95%, 4.63-62.5). There were statisti-
cally significative differences between intervention B versus control (p< 0.0001), 1.74 
(IC95%, 1.47-2.17). ConClusions: The knowledge about the correct performance 
of inhalation techniques is poor in patient with COPD. The performance of a correct 
inhalation technique improves with monitor training.
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objeCtives: To evaluate the clinical effectiveness of Kanakasava and 
Swasanandam Gulika in Bronchial Asthma. Methods: A randomized single blind 
clinical study with pretest and posttest design in 2 groups’s standard and trail were 
adopted, where the patients were given treatment with specific duration with 
follow up. In total 342 patients were selected from the OPD and IPD of Muniyal 
Institute of Ayurveda Medical Sciences Manipal enrolled for the present study out 
of which 22 were dropped out from the study. Routine hematological, bio-chemical 
and urine analysis were recorded. The main Signs and Symptoms Breathlessness, 
Wheezing, cough, Sneezing, Dysponea, head ache, were taken for assessment as 
symptoms grade parameters. Peak expiatory flow rate (PEFR), Absolute Eosinophil 
count (AEC), and ESR also taken for the assessment as Laboratory parameters. Data 
obtained from the above mentioned study was statistically analyzed by using the 
Z test. Results: Kanakasava and Swasanandam Gulika provided 67.5%. relief 
in Wheezing, 75.86% relief in Dysponea , 66.07%, relief in cough, 54.78% relief 
in Sneezing and 43.22% relief in Head ache which were statistically highly sig-
nificant result p< 0.001, where as in PEFR, AEC and ESR provided 92.85%, 23% and 
35.89% relief respectively which were also statistically highly significant result 
p< 0.001. ConClusions: Kanakasava and Swasanandam Gulika appear to be 
beneficial in Bronchial Asthma along with its symptoms. Bronchial Asthma is 
considered as chronic airway inflammatory disease. The effects in every condition 
and in complications are still being evaluated.
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objeCtives: Respiratory diseases, including asthma and chronic obstructive pul-
monary disease (COPD), cause about 1 million deaths annually in the WHO European 
Region. Xanthines (e.g. theophylline, aminophylline) are recommended for treating 
severe exacerbations of COPD, when short-acting bronchodilators do not produce 
rable to mepolizumab 250mg. Active treatments were comparable regarding asthma 
exacerbations and discontinuations due to AE.
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objeCtives: Several monoclonal antibodies (mAb) are in development for the 
treatment of uncontrolled asthma. Network meta-analysis (NMA) will become una-
voidable to compare effectiveness of these products. It could only be performed if 
studies define outcomes similarly. The objective of this research is to review the 
consistency of exacerbation definition used in clinical trials of mAb. Methods: All 
mAbs approved or in phase II/III development in asthma were identified through 
a systematic review in Medtrack® database. Clinical trials were identified through 
the clinical.trials.gov registry. Exacerbation definition was searched for all identified 
trials through targeted literature search. Definitions were compared to the current 
European Respiratory Society, American Thoracic Society and Global Initiative for 
Asthma guidelines. Results: Sixteen mAbs were identified in phase II/III devel-
opment for asthma. Omalizumab is the only mAb approved for asthma and its 
pivotal trials occurred over 10 years ago. 95 clinical trials have been registered for 
these mAbs with 52 trials using exacerbation as a clinical endpoint. Exacerbation 
definitions were retrieved for 25 trials, among which 40% of trials defined clinical or 
clinically relevant exacerbation, 12% defined severe exacerbations and 48% defined 
exacerbation without specification of severity or clinical relevance. Definitions used 
in trials were not aligned with current guideline definitions, and were inconsistent 
between studies. Criteria used to define exacerbation included: rescue systemic 
corticosteroid, use of nebulization therapy, hospital or emergency room admission, 
unscheduled medical intervention, unscheduled outpatient visits, increased daily 
dose of rescue inhalers, worsening of symptoms, peak expiratory flow or FEV1 dete-
rioration. ConClusions: High variability of outcome definitions suggests future 
hurdles for mAb to generate comparative effectiveness through NMA. Head-to-head 
comparison of the products reaching market in the next years is not expected, and 
health technology assessment around the extent of additional benefit might be 
challenging.
PRS8
BayeSIan neTWoRK meTa-analySIS To aSSeSS The ComPaRaTIve 
effICaCy and SafeTy of TReaTmenTS foR ChRonIC oBSTRuCTIve 
PulmonaRy dISeaSe
Taieb V1, Belhadi D1, Nielsen AT2, Hemels M2, Van Laer J3
1Amaris, London, UK, 2Janssen-Cilag A/S, Birkerød, Denmark, 3Janssen Pharmaceutica N.V., 
Beerse, Belgium
objeCtives: To assess the comparative efficacy and safety of inhaled corticoster-
oids and long-acting beta-agonist (ICS/LABA) fixed doses combination and phos-
phodiesterase-4 inhibitor for chronic obstructive pulmonary disease (COPD), using 
a Bayesian network meta-analysis. Methods: A systematic literature review was 
conducted according to NICE guidelines. Outcomes of interest included through 
forced expiratory volume in one second (FEV1), COPD exacerbations and discon-
tinuations due to adverse events (AE). Networks of evidence were based on treat-
ment- and dose-specific nodes except for budesonide/formoterol for which different 
devices were combined. Interpretation of results was based on absolute differences/
ratios and Bayesian probabilities for treatments to perform better than others (P), 
where P≤ 15% indicated a smaller effect and P≥ 85% a larger effect. Vague prior dis-
tributions were used. Selection of fixed versus random effects was based on the 
Deviance Information Criterion (DIC). Results: 6/9/5 studies reported results at 
16/26/52 weeks respectively. Analyses indicated that ICS/LABA were associated 
with higher improvement in FEV1 (D) compared to roflumilast (D: 0.050L to 0.060L, 
P≥ 94%), ICS/LABA were comparable to each other and all active treatments per-
formed better compared to placebo. In terms of COPD exacerbations, at 26 weeks, 
active treatments were overall comparable and performed better than placebo. At 
52 weeks, salmeterol/fluticasone propionate had lower COPD exacerbation rates 
than roflumilast (OR: 0.52, P= 94%). ICS/LABA were associated with lower discon-
tinuations due to AE rates compared to roflumilast (OR: 0.10 to 0.30, P≥ 98%). Among 
ICS/LABA, mometasone furoate/formoterol 200/10µg had a lower rate of discon-
tinuations compared to salmeterol/fluticasone propionate and fluticasone furo-
ate/vilanterol. ConClusions: This network meta-analysis of treatment in COPD 
suggested that ICS/LABA were associated with better efficacy and safety compared 
to roflumilast. However, roflumilast trials mainly focused on Asian patients and 
more severe populations which may have impacted the treatment effect observed.
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objeCtives: Previous studies have demonstrated substantial variation of the rela-
tive efficacy of widely used drugs over time. Changes in population characteristics or 
variation in the placebo response may be potential influencers. We used tiotropium 
as a treatment to examine this phenomenon as it has commonly been used as a 
reference treatment over time in Chronic Obstructive Pulmonary Disease (COPD). We 
aimed to assess the evolution of the relative efficacy of inhaled tiotropium against 
placebo, between launch and the latest assessment. Methods: We performed a 
systematic literature review of randomized-controlled trials (RCTs) of adults suffer-
ing from COPD in Medline from 2000 (launch) to 2012. RCTs evaluating tiotropium 
18 µg as a maintenance treatment for COPD were included in the analyses. Efficacy 
